Summary
EudraCT Number: 2006-000220-14
Sponsor's Protocol Code Number: TT 04
National Competent Authority: Denmark - DHMA 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2006-02-21
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000220-14/DK/

A. Protocol Information
A.1 Member State Concerned: Denmark - DHMA
A.2 EudraCT number: 2006-000220-14
A.3 Full title of the trial: A therapeutic and pharmacokinetic study of Savene (dexrazoxane) in the treatment of accidental anthracycline extravasation
A.4.1 Sponsor's protocol code number: TT 04
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: TopoTarget A/S
B.1.3.4	Country: Denmark
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Information not present in EudraCT
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: Yes
D.2.5.1 Orphan drug designation number: EU/3/01/059
D.3 Description of the IMP
D.3.1 Product name: Savene
D.3.4 Pharmaceutical form: Powder and solvent for solution for infusion
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Dexrazoxane
D.3.9.1 CAS number: 24584-09-6
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.3 Concentration number: 500 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: Information not present in EudraCT
D.3.11.8 Extractive medicinal product: Information not present in EudraCT
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Accidental extravasation of anthracyclines
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 7.1
E.1.2 Level: pref
E.1.2 Classification code: 10022062
E.1.3 Condition being studied is a rare disease: Yes
E.2 Objective of the trial
E.2.1 Main objective of the trial: To examine pharmakokinetic parameter during the 3-day Savene treatment
E.2.2 Secondary objectives of the trial: To observe the efficacy of Savene treatment
To evaluate safety issues of the Savene tretment
E.2.3 Trial contains a sub-study: Information not present in EudraCT
E.3 Principal inclusion criteria: 1. Cancer patients in chemotherapy with anthracyclines
2. Extravasation (leakage) of anthracycline suspected according to:
    a) a primary assessment by the physician
    b) presence of at least one of the following symptoms - pain, swelling, or redness 
        at the site where the anthracycline leakage is suspected to have occured
    OR
    suspicion of anthracycline extravasation from a central venous access device
3. The Savene treatment must be started within 6 hours after the accident
4. Age more or equal to 18 years
5. Performance status 2 or less
6. Informed consent

E.4 Principal exclusion criteria: 1. Known allergy towards dexrazoxane
2. reasonable suspision of extravasation of other vesicant compounds than 
    anthracyclines through the same intravenous access
3. AST or ALT, bilirubin, alkaline phosphatase > 3 x upper normal value
4. WBC < or equal to 1.5 x 1o 9/L and platelets < or equal to 75 x 10 9/L
5. Administration of dexrazoxane within the last 3 weeks or administration of other 
    extravasation treatments than those described in the protocol
6. Pregnant or breast feeding women
7. Women of childbearing age and potential, who do not use an efficient contraceptive (such as oral contraception, IUD intrauterine device, depot of gestagen, vaginal hormone ring or transdermal depot patch) for at least 7 days after the dexrazoxane treatment. 
A pregnancy test should be performed on day 1, if possible by a dipstick method to be read immediately. However, treatment should not be delayed.


E.5 End points
E.5.1 Primary end point(s): Obtainment of a pharmacokinetic profile for the three-day Savene
The prevention of: 
surgical intervention due to the extravasation incident 
and/or 
necrosis due to the event
late sequelae
postponement of planned cytostatic treatment
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: No
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: Yes
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: Information not present in EudraCT
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: No
E.7.1.2 Bioequivalence study: No
E.7.1.3 Other: No
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): Yes
E.7.3 Therapeutic confirmatory (Phase III): No
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: No
E.8.1.2 Open: Yes
E.8.1.3 Single blind: No
E.8.1.4 Double blind: No
E.8.1.5 Parallel group: No
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): No
E.8.2.2 Placebo: No
E.8.2.3 Other: No
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.5 The trial involves multiple Member States: No
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: No
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.7 Trial has a data monitoring committee: Information not present in EudraCT
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: The trial will be finished at day 42
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 1
E.8.9.1 In the Member State concerned months: 6
E.8.9.1 In the Member State concerned days: 
E.8.9.2 In all countries concerned by the trial years: 1
E.8.9.2 In all countries concerned by the trial months: 6

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Information not present in EudraCT
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Information not present in EudraCT
F.3.3.1 Women of childbearing potential not using contraception : No
F.3.3.2 Women of child-bearing potential using contraception: Information not present in EudraCT
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 15
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 15
F.4.2.2 In the whole clinical trial: 15

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2006-03-23
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2006-02-15

P. End of Trial
P. End of Trial Status: Completed
P. Date of the global end of the trial: 2007-05-30

